Australian Federal Court upholds BRCA1 gene as patent worthy

In the landmark Australian case, Cancer Voices Australia (ABN 93 322 703 427) & Anor v Myriad Genetics Inc & Ors, the Federal Court of Australia has ruled in favor of Myriad Genetics saying that patent claims directed to the gene BRCA1, a human breast and ovarian cancer disposing gene to be worthy of a patent.

Amongst all the criteria for patentability, when it comes to patenting gene or genetic sequences, “subject matter” has been the most controversial. Also, subject matter with respect to gene patents is treated very differently from legislation to legislation….read more on Patent Pill

Contributed by:

Sneha